Hepatocellular Carcinoma

Scoring systems based on behavioral and clinical data outperformed existing scores in predicting risk for hepatocellular carcinoma in patients with chronic hepatitis B virus infection, according to data presented at the EASL Congress.

CHICAGO — Individuals with high-risk hepatocellular carcinoma undergoing curative-intent procedures did not experience clinically meaningful deterioration in quality of life or function after adjuvant therapy, phase 3 study results showed.

In this video, Daneng Li, MD, a medical oncologist at City of Hope, discussed results from the Phase 3 IMbrave050 trial presented at American Association for Cancer Research Annual Meeting.

Foreign-born patients with hepatocellular carcinoma had higher survival rates than those born in the United States, according to data published in JNCI: Journal of the National Cancer Institute.

CHICAGO — Reported cases of hepatocellular carcinoma decreased significantly in 2020 compared with years before the COVID-19 pandemic, although there was minimal impact on tumor stage and patients receiving curative treatment.

In this video, Thomas Marron, MD, PhD, discussed the larger implications of hepatocellular carcinoma treatments presented at American Association for Cancer Research Annual Meeting.

In this video, Thomas Marron, MD, PhD, discussed data he presented on patients with liver cancer treated with neoadjuvant cemiplimab (Libtayo, Regeneron) at American Association for Cancer Research Annual Meeting.

In this video, Thomas Marron, MD, PhD, discussed results from the phase 3 IMbrave050 study, presented at American Association for Cancer Research Annual Meeting.

In this video, Ahmed Kaseb, MD, CMQ, discussed results from the phase 3 IMbrave050 trial, presented at American Association for Cancer Research Annual Meeting.

In this video, James Cleary, MD, PhD, a medical oncologist at Dana-Farber Cancer Institute, discussed results from the phase 3 IMbrave050 trial, presented at American Association for Cancer Research Annual Meeting.